DJS Law Group says Capricor investors may join securities class action
A DJS Law Group press release says investors in Capricor Therapeutics may pursue claims tied to alleged misstatements about Deramiocel and a BLA filing.
DJS Law Group says Capricor Therapeutics investors who bought shares during a stated class period may contact the firm about a securities lawsuit.
What happened
DJS Law Group said on Aug. 31, 2026, that investors in Capricor Therapeutics, Inc. may pursue a securities class action over alleged false and misleading statements about Deramiocel and the company’s biologics license application process.
The attorney-advertising press release says the case concerns shares of Capricor, which trades on Nasdaq under the ticker CAPR, purchased between Dec. 17, 2025 and July 26, 2026. It says the complaint alleges violations of Section 10(b) and Section 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5.
What the notice says
The notice asks shareholders who bought CAPR during the stated class period to contact the firm about possible lead plaintiff appointment. It also says lead plaintiff status is not required to participate in any recovery if the case moves forward.
Background
According to the release, the complaint alleges that Capricor made false and misleading statements to the market, modified the statistical analysis plan used to analyze clinical data for Deramiocel, and did not obtain FDA agreement to that change before resubmitting a biologics license application for the drug.
The brief provided does not include a court docket, a judge’s order or independent confirmation of the underlying allegations. The claims in the release remain allegations.
What the firm said
The release identifies DJS Law Group as the source of the notice and gives contact information for David J. Schwartz in Eastchester, New York. It does not include a quoted statement from Capricor.
What happens next
According to the notice, shareholders who purchased CAPR during the class period can contact the firm about potential lead plaintiff appointments. The release does not provide further case dates or court deadlines.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
Comments ()